To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Hemicrania continua (HC) is a persistent unilateral headache that responds to indomethacin. It is usually unremitting, but rare cases of remission have been documented. Hemicrania continua is considered a primary headache disorder, meaning that it's not caused by another condition.
Additional recommended knowledge
International Headache Society's International Classification of Headache Disorders 2nd Edition, establishes the following diagnostic criteria for hemicrania continua:
Hemicrania continua was first described in 1981, at that time around 130 cases were described in the literature. However, rising awareness of the condition has led to increasingly frequent diagnosis in headache clinics, and it seems that it is not as rare as these figures would imply. The condition occurs more often in women than men and tends to first present in adulthood, although it has also been reported in children as young as 5 years old.
Cause and diagnosis
The cause of hemicrania continua is unknown. There is no definitive diagnostic test for hemicrania continua. Diagnostic tests such as imaging studies may be ordered to rule out other causes for the headache. When the symptoms of hemicrania continua are present, it's considered "diagnostic" if they respond completely to indomethacin.
The factor that allows hemicrania continua and its exacerbations to be differentiated from migraine and cluster headache is that hemicrania continua is completely responsive to idomethacin. Triptans and other abortive medications do not affect hemicrania continua.
In addition to persistent daily headache of HC, which is usually mild to moderate, HC can present other symptoms. These additional symptoms of HC can be divided into three main categories:
Hemicrania continua generally responds only to indomethacin 25-300 mg daily, which must be continued long term. Unfortunately, gastrointestinal side effects are a common problem with indomethacin, which may require additional acid-suppression therapy to control.
In patients who are unable to tolerate indomethacin, the use of celecoxib 400-800 mg per day (Celebrex) and rofecoxib 50 mg per day (Vioxx - no longer available) have both been shown to be effective and are likely to be associated with fewer GI side effects. There have also been reports of two patients who were successfully managed with topiramate 100-200 mg per day (Topamax) although side effects with this treatment can also prove problematic.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hemicrania_continua". A list of authors is available in Wikipedia.|